TRDA · Entrada Therapeutics, Inc.
$7.58
-0.02 (-0.26%)
At close · Aug 21
Market Cap
$295.92M
Shares
38.94M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.60
Open$7.76
Day$7.30–7.77
52W close$5.06–16.03
Avg vol 30d397K
Short int2.1M · 5.5% float · 4.3d
Short vol55%
Last earningsMay 7, 2026
DataOct 2021–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
+9%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
23%
mid-range
Momentum
relative strength
1-month return
+26%
trailing
6-month return
−36%
trailing
YTD return
−26%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +27 funds added
Insider flow
Distributing
Net -$3.1M over 90 days · 100% sells
Short interest
Falling
5.51% of float · ▼ -3.9% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
128 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−88%
Y/Y
EPS growth
−307%
Y/Y
Free cash flow
$-129.6M
Balance sheet
$90.4M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +27 funds added
Insider flow
Distributing
Net -$3.1M over 90 days · 100% sells
Short interest
Falling
5.51% of float · ▼ -3.9% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
128 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $8 · 23%
Range high $16
vs 200-day avg -22%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRDA
this stock
Entrada Therapeutics, Inc.
|
$295.92M | -26.1% | -87.9% | — | 5.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.4% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRDA | +2.0% | +25.6% | -36.3% | +11.9% | -26.1% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.0% | +22.3% | -47.5% | +9.9% | -37.9% |
Key facts
CIK
1689375
CUSIP
29384C108
13F (30d)
119 filings
119 filers
Visit website
Investor relations